Wolfe Research starts Moderna at Underperform, sees limited upside opportunity
Wolfe Research analyst Alexandria Hammond initiated coverage of Moderna (MRNA) with an Underperform rating and $40 price target Moderna may ...
pharmaphorum2d
US govt gives $176m to Moderna for bird flu vaccine
The US government has signed a $176 million deal with Moderna to develop an mRNA-based pandemic influenza vaccine, as reports emerge of a fifth human case of H5N1 flu linked to ongoing outbreaks ...
Bird Flu Puts Teen In Critical Condition As Canada Reports First Human Case: What You Need To Know
Pfizer and Moderna are hustling to develop an mRNA bird flu vaccine, the same technology used in the companies' respective ...
Scientific American15d
A Bird Flu Vaccine Might Come Too Late to Save Us from H5N1
If the influenza virus infecting cattle workers starts a pandemic, help in the form of a vaccine is months away ...
Novavax to Move Forward With Covid-19-Flu Vaccine After FDA Lifts Clinical Hold -- Update
Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...
Canada approves Moderna's RSV vaccine for those age 60 and older, company says
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
KSL3d
FDA lifts clinical hold on Novavax's combo COVID-flu shot
The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...
BioSpace7d
Moderna Gets Better-Than-Expected Q3 COVID-19 Vaccine Sales, but RSV Shot Disappoints
While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...
Business Times7d
Moderna reports surprise profit on higher-than-expected Covid vaccine sales
MODERNA reported a surprise third-quarter profit on Thursday (Nov 7), driven by cost cutting and higher-than-expected sales ...
FDA Gives Green Signal To Novavax's COVID-19-Influenza Combo Vaccine Late-Stage Trial
On Monday, the FDA removed the clinical hold on Novavax Inc.’s (NASDAQ:NVAX) Investigational New Drug (IND) application for ...
Business Insider8d
Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
Seasonal flu + COVID vaccine: Moderna shared positive Phase 3 immunogenicity data for its flu/COVID combination vaccine at its 2024 R&D Day event. Seasonal flu vaccine: The Company has initiated a ...